5 Questions on Small-Cell Lung Cancer
Among patients with SCLC, what characterizes never smokers? What effect did bevacizumab have when added to standard of care? Test your knowledge in our latest quiz.
Among patients with small-cell lung cancer (SCLC), what characterizes never smokers? What effect did bevacizumab have when added to standard of care? Test your knowledge in our latest quiz.
Question 1
Answer and Question 2 on Next Page »
Answer
A. 2 to 4 months. From the start of treatment, only about 10% of SCLC patients will remain free of disease at 2 years, according to the National Cancer Institute’s treatment summary on SCLC.
Question 2
Answer and Question 3 on Next Page »
Answer
B. Extent of disease. The National Cancer Institute’s treatment summary on SCLC notes that patients with limited-stage disease have a better prognosis than extensive-stage patients. Patients with limited-stage disease have a median survival of 16 to 24 months, and 5-year survival is 14%. Patients with extensive-stage disease have a median survival of 6 to 12 months, and long-term disease-free survival is rare in these patients.
Question 3
Answer and Question 4 on Next Page »
Answer
C. Pravastatin. The study found that although 40-mg pravastatin combined with standard-of-care therapy for SCLC was safe, it did not benefit patients. The results confirmed the conclusions of four smaller trials.
Question 4
Answer and Question 5 on Next Page »
Answer
B. Improved progression-free survival. Median progression-free survival times were 5.7 months in the arm without bevacizumab and 6.7 months in the arm with bevacizumab (P = .030). Although the study did not meet its primary endpoint of overall survival, the authors noted that a significant effect of bevacizumab on overall survival was observed among patients who received maintenance bevacizumab, warranting further research in this setting.
Question 5
Answer
D. All of the above. Among the never smokers, prognosis was relatively favorable, and overall survival was statistically longer than that of smokers, according to the study. Only one of the eight patients had an EGFR mutation.
Quiz: Best Second-Line Tx for Metastatic Lung SCC and Crohn Disease?
March 1st 2018Are there special second-line considerations for an SCC lung patient with a history of Crohn disease who progressed on first-line carboplatin and gemcitabine? Can any pretreatment tests be deferred for a patient with a history of heavy smoking and a single solitary nodule found on his CT chest scan? Take this multiquestion quiz to find out.
Quiz: Are EGFR Mutations and ALK Rearrangements in Lung Cancer Mutually Exclusive?
February 1st 2018Know when to change targeted therapies in patients with progressive lung cancer? How about appropriate patient criteria for segmentectomy or wedge resection? Test your knowledge in our latest quiz.
